{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liao GZ"],"funding":["National High Level Hospital Clinical Research Funding","Chinese Academy of Medical Science Innovation Fund for Medical Science","Beijing Natural Science Foundation"],"pagination":["343"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11495105"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(1)"],"pubmed_abstract":["<h4>Background</h4>The association between plasma free fatty acid (FFA) and the outcomes in the heart failure (HF) patients remains unclear.<h4>Methods</h4>A cohort study among HF patients was performed. Plasma FFA was analyzed as both a continuous and a categorical variable (grouped by tertiles) to assess its association with composite cardiovascular (CV) death and HF hospitalization (CV death & HHP), CV death alone, and all-cause mortality (ACM) using Cox regression models. Subgroup analyses of HF patients with preserved ejection fraction (HFpEF) and mildly reduced/reduced ejection fraction (HFmrEF/HFrEF) were performed. This work also assessed the effectiveness of combining FFA and NT-pro BNP biomarkers for risk stratification by calculating the concordance index (C-index).<h4>Results</"],"journal":["Lipids in health and disease"],"pubmed_title":["Free fatty acids: independent predictors of long-term adverse cardiovascular outcomes in heart failure patients."],"pmcid":["PMC11495105"],"funding_grant_id":["2021-CXGC08","7222143","2022-GSP-GG-9"],"pubmed_authors":["Huang Y","Zhou Q","Liu HH","Zhou P","Zhang J","Zhang YH","Liao GZ","Zhai M","Wang JX","Feng JY","He CH","Zhuang XF"],"additional_accession":[]},"is_claimable":false,"name":"Free fatty acids: independent predictors of long-term adverse cardiovascular outcomes in heart failure patients.","description":"<h4>Background</h4>The association between plasma free fatty acid (FFA) and the outcomes in the heart failure (HF) patients remains unclear.<h4>Methods</h4>A cohort study among HF patients was performed. Plasma FFA was analyzed as both a continuous and a categorical variable (grouped by tertiles) to assess its association with composite cardiovascular (CV) death and HF hospitalization (CV death & HHP), CV death alone, and all-cause mortality (ACM) using Cox regression models. Subgroup analyses of HF patients with preserved ejection fraction (HFpEF) and mildly reduced/reduced ejection fraction (HFmrEF/HFrEF) were performed. This work also assessed the effectiveness of combining FFA and NT-pro BNP biomarkers for risk stratification by calculating the concordance index (C-index).<h4>Results</","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-07-16T07:24:22.21Z","creation":"2025-04-07T01:23:39.274Z"},"accession":"S-EPMC11495105","cross_references":{"pubmed":["39438940"],"doi":["10.1186/s12944-024-02332-5"]}}